Suudi Arabistan - İngilizce - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda austria gmbh - distigmine bromide - injection - 0.5 mg

Japonya - İngilizce - すりの適正使用協議会 RAD-AR Council, Japan

torii pharmaceutical co.,ltd - distigmine bromide - limpid and colorless ophthalmic solution

Japonya - İngilizce - すりの適正使用協議会 RAD-AR Council, Japan

torii pharmaceutical co.,ltd - distigmine bromide - limpid and colorless ophthalmic solution

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy.*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: macrogol 400; magnesium stearate; lactose monohydrate; crospovidone; titanium dioxide; sucrose; polysorbate 80; povidone; colloidal anhydrous silica; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; polysorbate 80; lactose monohydrate; macrogol 400; povidone; sucrose; hypromellose; magnesium stearate; titanium dioxide - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 400; crospovidone; magnesium stearate; lactose monohydrate; polysorbate 80; colloidal anhydrous silica; hypromellose; povidone; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; titanium dioxide; magnesium stearate; macrogol 400; polysorbate 80; hypromellose; lactose monohydrate; povidone; colloidal anhydrous silica; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; polysorbate 80; sucrose; colloidal anhydrous silica; macrogol 400; povidone; titanium dioxide; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.